Product image of Mesar Plus (Olmesartan Medoxomil, Hydrochlorothiazide) supplied by GNH India

Mesar Plus

Active Ingredient:
Olmesartan Medoxomil, Hydrochlorothiazide
Origin:
EU

Mesar Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil and hydrochlorothiazide, the active ingredients in Mesar Plus, are an angiotensin II receptor blocker and a thiazide diuretic presented as an oral tablet for systemic use. They are indicated for the management of hypertension in adult patients, helping to lower elevated blood pressure and reduce cardiovascular risk.

GNH India supplies Mesar Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable logistics for global distribution.

Manufacturer / TM Owner

Menarini International Operations Luxembourg S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mesar Plus combines an ARB and a thiazide diuretic to treat conditions within the hypertension disease family.

  • Hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension.
  • Essential hypertension: provides effective blood pressure control when monotherapy is insufficient.
  • Hypertension requiring combination therapy: offers a convenient single‑tablet regimen to improve adherence.

How It Works

  • Olmesartan medoxomil selectively blocks the AT1 receptor, preventing angiotensin II from causing vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits NaCl reabsorption in the distal convoluted tubule, promoting diuresis and reducing plasma volume. The combined actions result in decreased peripheral resistance and lowered blood pressure.

Side Effects

Mesar Plus may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

  • Dizziness: sensation of light‑headedness, especially after standing.
  • Headache: mild to moderate pain in the head region.
  • Fatigue: feeling unusually tired or weak.
  • Increased urination: more frequent need to void.
  • Electrolyte imbalance: changes in potassium or sodium levels.
  • Dry mouth: reduced salivation.

Serious or Rare Side Effects

  • Severe hypotension: dangerously low blood pressure.
  • Acute kidney injury: sudden decline in renal function.
  • Hyperkalemia: elevated potassium concentration.
  • Angioedema: swelling of face, lips, or airway.
  • Pancreatitis: inflammation of the pancreas.
  • Hepatic dysfunction: abnormal liver enzyme elevations.

Precautions & Warnings

Before prescribing Mesar Plus, clinicians should consider several safety factors.

  • Renal function: assess baseline renal function and monitor periodically.
  • Electrolytes: monitor serum potassium and sodium levels during therapy.
  • Pregnancy: avoid use unless the potential benefit justifies the risk to the fetus.
  • Elderly: initiate at a lower dose and watch for orthostatic hypotension.
  • Concomitant NSAIDs: may attenuate the antihypertensive effect.
  • Store at ambient temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Mesar Plus can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid)

  • Aliskiren (in patients with diabetes): increased risk of renal impairment.
  • Potassium‑sparing diuretics: risk of hyperkalemia.
  • Lithium: heightened lithium toxicity.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: additive blood‑pressure‑lowering effect.
  • Calcium channel blockers: enhanced antihypertensive response.

Frequently Asked Questions

Mesar Plus is prescribed to lower high blood pressure in adult patients. It combines an angiotensin II receptor blocker with a thiazide diuretic, providing a dual mechanism that helps control hypertension, especially when a single‑agent therapy is insufficient.

Olmesartan medoxomil blocks the AT1 subtype of angiotensin II receptors, preventing the hormone from causing blood‑vessel constriction and aldosterone‑mediated sodium retention. This leads to vasodilation and reduced fluid volume, contributing to lower blood pressure.

The specific dose of Mesar Plus is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and other individual factors. Patients should follow the dosage instructions provided by their healthcare professional.

The safety of Mesar Plus during pregnancy or lactation has not been established. It should only be used if the potential benefit outweighs the possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Mesar Plus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mesar Plus offers a fixed‑dose combination of an ARB and a thiazide diuretic, which can improve adherence compared with taking two separate tablets. It provides complementary mechanisms—vascular relaxation and diuresis—often resulting in more effective blood‑pressure control than monotherapy with either class alone.

Store Mesar Plus at ambient temperature, preferably below 25 °C, in the original container to protect it from moisture and light. Keep the tablet out of reach of children and do not use it after the expiration date printed on the packaging.

Mesar Plus is taken orally, usually once daily, with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.

Serious risks include severe hypotension, acute kidney injury, hyperkalemia, and angioedema, which can be life‑threatening. Patients should be monitored for signs of these conditions, especially during the initial treatment period or when dose adjustments are made.

Mesar Plus should be avoided in patients with known hypersensitivity to olmesartan, hydrochlorothiazide, or any component of the formulation. It is also contraindicated in individuals with severe renal impairment, hyperkalemia, or those taking certain potassium‑sparing agents without close medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Hydrochlorothiazide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT